免疫吸附剂治疗系统性红斑狼疮的临床试验。

Clinical trials of immunoadsorbent in systemic lupus erythematosus therapy.

作者信息

Gao C L, Li B A, Chen C Z, Yu Y T, Yuan P, Song J C

机构信息

Institute for Molecular Biology, Nankai University, Tianjin, China.

出版信息

Artif Organs. 1995 May;19(5):468-9. doi: 10.1111/j.1525-1594.1995.tb02360.x.

DOI:10.1111/j.1525-1594.1995.tb02360.x

PMID:7625928

Abstract

Five patients with systemic lupus erythematosus (SLE) were perfused through an extracorporeal shunt filled with DNA-immunoadsorbent (DNA immobilized on carbonized resin beads). High concentrations of anti-DNA antibodies (36.4-67.0%) (binding percentage with 125I-DNA) in the serum of SLE patients were reduced to 13.8-53.0%, respectively. The highest removal percentage was 62.1%. Although the decline levels varied, the symptoms of patients, i.e., long-term severe joint pain, severe edema, hydropericardium, and ascites were all relieved considerably. The immunoadsorbent showed satisfactory blood compatibility.

摘要

五名系统性红斑狼疮（SLE）患者通过充满DNA免疫吸附剂（固定在碳化树脂珠上的DNA）的体外分流器进行灌注。SLE患者血清中高浓度的抗DNA抗体（36.4 - 67.0%）（与125I - DNA的结合百分比）分别降至13.8 - 53.0%。最高清除率为62.1%。尽管下降水平有所不同，但患者的症状，即长期严重关节疼痛、严重水肿、心包积液和腹水均得到了显著缓解。该免疫吸附剂显示出令人满意的血液相容性。